Vivos Therapeutics, a leading medical device and healthcare services company, reported a 78% sequential quarter over quarter revenue growth in Q3 2025.
The revenue increase was driven by the first full quarter of operations since the acquisition of The Sleep Center of Nevada.
The strategic pivot towards medical sleep practices and testing centers showcased positive results in revenue and gross profit.
Revenue Growth
Sequential revenue growth of 78% in Q3 2025 and a 76% year-over-year revenue increase.
Operational Strategy
Shift from dental industry distribution channel to direct affiliation with medical sleep practices.
Financial Performance
Gross profit of $3.9 million in Q3 2025 and $7.6 million for the nine months ended September 30, 2025.
Market Expansion
Plans to expand operations in Las Vegas area and target additional major markets beyond.
- The acquisition of The Sleep Center of Nevada significantly expanded Vivos' patient reach and revenue streams.
- Higher expenses in the quarter were attributed to investments in people and infrastructure for operational optimization.
- Expectations for reduced cash burn and potential profitability in 2026 as new sleep optimization teams are added.
Vivos Therapeutics' strategic pivot and successful acquisition have positioned the company for continued growth and expansion in the sleep medical market. With a focus on operational optimization and revenue enhancement, Vivos is poised for a promising future.